For patients eligible for anticoagulant therapy with either a vitamin K antagonist anticoagulant, such as warfarin, or a non-vitamin K antagonist anticoagulant such as apixaban, dabigatran, edoxaban, or rivaroxaban, the non-vitamin K antagonist anticoagulants are preferred (class I recommendation).